KURA (29) ORIC (39) CYRX (38) ANRO (38) ⌘ Pro Terminal →

Aktis Oncology Inc. (AKTS) — RQD Stock Rating Cockpit

$16.85 +0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.82

Aktis Oncology Inc. (AKTS) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $937.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.82 (-0.16%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTS)Realized 20D OHLCV Swing Band: ±12%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY AKTS SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (27% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$18.15-17% Next Q

Q2 (-2Q)

Grade C$15.06+4.4% Next Q

Q3 (-1Q)

Grade C$15.73+7.1% Next Q

Current

Grade D+$16.85-0.4% Hist 90D α

Trajectory: C+ (64) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AKTS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, AKTS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.57) or 200D SMA ($21.01) invalidates the momentum regime and cuts Target Base ($16.70) toward Bear Floor ($13.03).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AKTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

36.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE11% OF RANGE

L: $15$16.85H: $34

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on AKTS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

18/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like AKTS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTS)

✓Walkthrough of AKTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AKTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.13%▼ DESCENDING CHANNEL

2026-10-30O $16.84H $17.07L $15.77C $16.85VOL 251.5K

RES: $21.98SUP: $13.78SMA50: $20.57SMA200: $21.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AKTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AKTS Butterfly Map → + Track AKTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AKTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AKTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AKTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTS)

Health Care Rank #266 of 1016 ⚔️ KURA vs AKTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AKTS vs. KURA, ORIC, CYRX, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aktis Oncology Inc. (AKTS) ranks #266 by composite RQD confidence (56/100, grade D+) and #369 by equity capitalization ($937.2M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AKTS ACTIVE Aktis Oncology Inc.	D+	56/100	—	—	—	+0.18%	$937.2M	Benchmark Subject
KURA Kura Oncology Inc.	E	29/100	—	—	-35.0%	-1.49%	$939.4M	/kura-vs-akts →
ORIC Oric Pharmaceuticals Inc.	D-	39/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-akts →
CYRX CryoPort Inc.	D-	38/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-akts →
ANRO Alto Neuroscience Inc.	D-	38/100	—	—	-35.0%	+0.60%	$921.0M	/anro-vs-akts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002035832

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aktis Oncology Inc. (AKTS) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, AKTS closed FY2025 with $264.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$264.9M	—

3. AKTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $16.85 (+0.18% 1D, market cap $937.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AKTS ranks #266 in composite RQD confidence.

How does AKTS compare to KURA and ORIC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KURA (Kura Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and ORIC (Oric Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AKTS?

Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AKTS trading relative to its 50-day, 200-day, and 52-week technical levels?

AKTS last traded at $16.85 (+0.18% on volume of 245,686 shares), positioning the stock -18.08% below its 50-day simple moving average ($20.57) and -19.80% below its 200-day simple moving average ($21.01). Across its 52-week range of $14.72 to $34.19, AKTS sits at the 10.9% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($14.83 to $18.87).

AKTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell AKTS stock right now?

Aktis Oncology Inc. (AKTS) currently earns a Roarable Rating of D+ (Sell — SELL) with 56/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is AKTS's 12-month price target and RQD AI Jury consensus?

AKTS's 12-month base price target is $16.7 (range $13.03 to $35.9), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: AKTS RQD Cockpit AKTS 12M Forecast AKTS Earnings & Move AKTS Dividends & DRIP AKTS Insiders & 13F AKTS Whale Options AKTS Profit Sankey AKTS News & Why